secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2026-08-12T20:10:20+00:00
Accession:  0001193125-26-346859
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Q2 2026 net loss $18.0M; cash $90.0M funds into Q4 2027
---------------------------------------------------------------

- Net loss $18.0M vs $21.0M in Q2 2025; R&D expense $13.8M vs $16.2M prior year.
- Cash, equivalents and investments $90.0M as of Jun 30, 2026, expected to fund ops into Q4 2027.
- ACR-368 Phase 2b prespecified interim analysis in serous EC on track for H2 2026; Phase 3 initiation planned H1 2027.
- ACR-2316 entered randomized dose expansion at 120mg and 160mg oral QD in AP3-prioritized tumor types.
- IND filing for CDK11 inhibitor candidate planned H1 2027; additional AP3 programs to start in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/0001193125-26-346859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526346859/acrv-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-346859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer